Disease × agent evidence record

In-Lab Instrumental Activities Of Daily Living Training for Long COVID: evidence, trials and status

Trials of In-Lab Instrumental Activities Of Daily Living Training in Long COVID are registered but none has completed, so there is no outcome evidence from those studies yet; the record is a signal of research interest.

1registered trials
0recruiting
1publications
CEvidence tier · Preliminary
10.0Score
Research map, not treatment advice. This page aggregates registry and literature records. It does not evaluate efficacy, dosing or safety for any individual. Discuss any treatment decision with a qualified clinician.

Summary

In-Lab Instrumental Activities Of Daily Living Training is tracked by OSMF as an investigational option for Long COVID; no regulator has approved it for this indication, and most post-viral conditions have no approved disease-modifying therapy at all. ClinicalTrials.gov lists 1 registered trial linking In-Lab Instrumental Activities Of Daily Living Training to Long COVID: 1 is active or not yet recruiting. None of the registered studies carries a drug-development phase label, which is typical for behavioural, device and supplement protocols. It plans or enrolled 40 participants. Registered activity dates to 2024. The literature layer holds 1 publication for this pair: 1 clinical trial publication. These are primary trial reports rather than syntheses, so results have not yet been pooled or graded independently.

Long COVID / PASC is tracked on the OSMF post-viral programme alongside ME/CFS, Long COVID, POTS and MCAS. Across the programme, 426 candidate agents are logged for Long COVID, most of them preliminary; this page isolates the record for one of them.

Evidence table

Evidence tierC · Preliminary
Evidence score10.0 (trials 3.0, literature 2.0, tier 5, approved bonus 0.0)
Registered trials1 total: 0 recruiting, 1 active / not yet recruiting, 0 completed, 0 other
Linked publications1 (1 clinical trial publication)
Agent typeBehavioural (Behavioral / Protocol / Exercise)
Development stage (any indication)Investigational
Mechanism / classNeurological / Autonomic
Data sourcesOSMF therapeutic agent database, ClinicalTrials.gov, PubMed
How the evidence score is calculated
  • Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
  • Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
  • The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
  • Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
  • The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.

Registered clinical trials

NCT IDTitleStatusPhaseEnrolment
NCT06095297Long COVID Brain Fog: Cognitive Rehabilitation Trial
University of Alabama at Birmingham · 2024
active, not recruitingNot applicable40

Search ClinicalTrials.gov for newer studies

Published literature

Run the live PubMed search

Mechanism and notes

Recorded mechanism or class: Neurological / Autonomic.

Clinical notes: Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.

Safety: Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.

Dosing in studies: See linked studies/trials for reported doses and durations; typical protocols vary widely.

Frequently asked questions

Is In-Lab Instrumental Activities Of Daily Living Training approved for Long COVID?

In-Lab Instrumental Activities Of Daily Living Training is tracked by OSMF as an investigational option for Long COVID; no regulator has approved it for this indication, and most post-viral conditions have no approved disease-modifying therapy at all. Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.

Is In-Lab Instrumental Activities Of Daily Living Training in clinical trials for Long COVID?

ClinicalTrials.gov lists 1 registered trial linking In-Lab Instrumental Activities Of Daily Living Training to Long COVID: 1 is active or not yet recruiting. None of the registered studies carries a drug-development phase label, which is typical for behavioural, device and supplement protocols. It plans or enrolled 40 participants. Registered activity dates to 2024.

What does the evidence show for In-Lab Instrumental Activities Of Daily Living Training in Long COVID?

Trials of In-Lab Instrumental Activities Of Daily Living Training in Long COVID are registered but none has completed, so there is no outcome evidence from those studies yet; the record is a signal of research interest. OSMF's existing evidence tier for this pair is C (Preliminary), taken from the OSMF therapeutic agent database, which grades agents by the volume and design of condition-specific evidence rather than by effect size.

Cite this page

Open Source Medicine Foundation. In-Lab Instrumental Activities Of Daily Living Training for Long COVID: evidence, trials and status. OSMF Research Tracker. Updated 2026-11-22. https://research.opensourcemed.info/pairs/long-covid/in-lab-instrumental-activities-of-daily-living-training.html

Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-11-22. Page built 2026-11-22.

Get OSMF research updates on Substack

This is a research map, not treatment advice. Evidence tiers and scores summarise what has been studied, not whether a treatment works or is safe for you.